Enliven Therapeutics Inc

For the period ended Dec 31, 2024. Filed Mar 13, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 13, 2025

ELVN$51.55+4.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	As of December 31,
	2024	2023
Assets
Current assets:
Cash and cash equivalents	$124,117	$100,141
Marketable securities	189,323	153,007
Restricted cash	54	54
Prepaid expenses and other current assets	4,633	2,949
Contingent value right asset	—	10,000
Total current assets	318,127	266,151
Property and equipment, net	458	742
Operating lease right-of-use assets	—	320
Deferred offering costs	—	563
Other long-term assets	7,175	4,091
Total assets	$325,760	$271,867
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$1,342	$532
Accrued expenses and other current liabilities	14,573	15,362
Contingent value right liability	—	10,000
Total current liabilities	15,915	25,894
Long-term liabilities	—	67
Total liabilities	15,915	25,961
Commitments and contingencies (Note 9)
Stockholders' equity:
Preferred stock, par value $0.001; authorized shares - 10,000,000;issued and outstanding shares - none	—	—
Common stock, par value $0.001; authorized shares - 100,000,000;issued and outstanding shares - 48,936,459 and 41,292,027 atDecember 31, 2024 and 2023, respectively	49	41
Additional paid-in capital	553,213	400,172
Accumulated other comprehensive income	55	141
Accumulated deficit	(243,472)	(154,448)
Total stockholders’ equity	309,845	245,906
Total liabilities and stockholders' equity	$325,760	$271,867

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.